XML 59 R44.htm IDEA: XBRL DOCUMENT v3.22.4
Business Combination - Narrative (Details) - Antares Pharma, Inc - USD ($)
$ / shares in Units, $ in Thousands
3 Months Ended 12 Months Ended
May 24, 2022
Dec. 31, 2022
Dec. 31, 2022
Business Acquisition [Line Items]      
Purchase consideration $ 1,045,668    
Consideration transferred, cash paid per acquiree share (in usd per share) $ 5.60    
Consideration related toacquiree closing indebtedness settled $ 19,683    
Consideration for seller transaction costs paid by Halozyme 22,906    
Transaction costs     $ 21,900
Contingent consideration, liability 130,000 $ 15,700 15,700
Change in contingent liability   $ 114,300  
Pro forma revenue of acquiree since acquisition date     112,700
Proforma earnings loss of acquiree since acquisition date     $ 67,600
Revolving Credit Facility      
Business Acquisition [Line Items]      
Credit facility, maximum borrowing capacity 350,000    
Term Loan Facility      
Business Acquisition [Line Items]      
Credit facility, maximum borrowing capacity $ 250,000